Chemical Component Summary

FormulaC13 H11 N3 O4
Molecular Weight273.24
Isomeric SMILESNc1cccc2C(=O)N([C@H]3CCC(=O)NC3=O)C(=O)c12

Chemical Details

Formal Charge0
Atom Count31
Chiral Atom Count1
Chiral AtomsC12
Bond Count33
Aromatic Bond Count6
Leaving Atomsn/a

Drug Info: DrugBank

DrugBank IDDB08910 Different stereochemistry
DescriptionPomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
Brand Names
  • Pomalyst
  • Imnovid
Affected OrganismHumans and other mammals
IndicationPomalidomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.
PharmacologyPomalidomide is more potent than thalidomide (100-times) and lenalidomide (10-times).
Mechanism of actionPromalidomide is an immunomodulatory agent with antineoplastic activity. It is shown to inhibit the proliferation and induce apoptosis of various tumour cells. Furthermore, promalidomide enhances T cell and natural killer (NK) cell-mediated immunity and inhibited the production of pro-inflammatory cytokines, like TNF-alpha or IL-6, by monocytes. The primary target of promalidomide is thought to be the protein cereblon. It binds to this target and inhibits ubiquitin ligase activity. It is also a transcriptional inhibitor of COX2.
Route of administrationOral
  • Acids, Carbocyclic
  • Angiogenesis Inhibitors
  • Angiogenesis Modulating Agents
  • Antineoplastic Agents
  • Antineoplastic and Immunomodulating Agents
CAS number19171-19-8
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682